Evidence map›Paper›PMID 39811505›Full record

ArticleWorld journal of gastroenterology2025

Prospects of elafibranor in treating alcohol-associated liver diseases.

Wei-Tong Cui, Hua-Ru Xue, Dian-Fang Wei, Xiao-Yu Feng, Kai Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Wei-Tong CuiSchool of Basic Medicine, Qilu Medical University, Zibo 255300, Shandong Province, China. klnr727@qlmu.edu.cn.
Hua-Ru XueSchool of Medical Imaging, Qilu Medical University, Zibo 255300, Shandong Province, China.
Dian-Fang WeiSchool of Basic Medicine, Qilu Medical University, Zibo 255300, Shandong Province, China.
Xiao-Yu FengSchool of Basic Medicine, Qilu Medical University, Zibo 255300, Shandong Province, China.
Kai WangSchool of Basic Medicine, Qilu Medical University, Zibo 255300, Shandong Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alcohol-related liver disease (ALD), which is induced by excessive alcohol consumption, is a leading cause of liver-related morbidity and mortality. ALD patients exhibit a spectrum of liver injuries, including hepatic steatosis, inflammation, and fibrosis, similar to symptoms of nonalcohol-associated liver diseases such as primary biliary cholangitis, metabolic dysfunction-associated steatotic liver disease, and nonalcoholic steatohepatitis. Elafibranor has been approved for the treatment of primary biliary cholangitis and has been shown to improve symptoms in both animal models and

Indexed as

BenzoatesLiver Diseases, AlcoholicAnimalsChalconesDisease Models, AnimalHumansLiverMicePropionatesTreatment Outcome2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acidBenzoatesChalconesPropionatesAlcohol-associated liver diseasesApoptosisElafibranorFibrosisInflammationLipidPeroxisome proliferator-activated receptorSteatosis

Identifiers

PMID39811505
PMCPMC11684193

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.